Dr Naureen Starling is a Consultant Medical Oncologist at The Royal Marsden specialising in treatment of gastrointestinal (GI) cancers and is a Reader within the Division of Clinical Studies at the Institute of Cancer Research.
Dr Starling graduated from University College London with First Class Honours in Physiology (BSc) and distinctions in Clinical Pharmacology/Therapeutics and Pathology. She undertook general medical training at University College Hospital and Northwick Park/St Mark’s hospitals and specialist training in Medical Oncology at The Royal Marsden. Her postgraduate degree at the ICR focused on the genomics and therapeutics of oesophageal cancer.
Her research interests in GI cancers (oesophageal, gastric, pancreatic and colorectal) are focused on earlier phase clinical trials, novel therapeutics/technologies and the delivery of individualised medicine to patients with gastrointestinal cancers. She is the principal investigator on numerous international clinical trials of novel drugs in oesophago-gastric, pancreatic and colorectal cancer. She is a member of several multi-centre clinical trial steering and safety review committees. Dr Starling has been a lead or co-applicant on a number of successful peer-reviewed research grant applications.
She is the Associate Director of Clinical Research for the Royal Marsden and serves on the UK National Cancer Research Institute oesophago-gastric and colorectal sub-groups. She has acted as a clinical expert in oesophago-gastric cancer for NICE (guideline committee and technology appraisal) and is a trustee for Pancreatic Cancer UK. She has been a faculty member of ESMO (GI), GI ASCO and ASCO.
Dr Starling also holds educational roles including NIHR Training Lead for the RM/Institute of Cancer Research Biomedical Research Centre, member of the ICR/Imperial College CRUK Major centre training committee, Training Program Director (one of four) for South London Medical Oncology Training and a member of the pan-London specialist Medical oncology training committee.